Neurosense Therapeutics is trading 5% up at $6.40 as U.S. futures point to a firmer pre-market tone.

  • S&P 500, Nasdaq Composite, and Dow Jones futures are all higher.
  • No new company-specific announcement for September 17, 2026 was identified.
  • Trading remains unusually volatile following the 1-for-20 reverse split, effective September 14, which reduced shares outstanding to approximately 1.9 million.